Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

 
Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization
 

This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.
 
How to report

You can send the case reports using the following tools:
 
  1. For Healthcare Professionals and the Public
The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.
 
  1. The VigiMobile e-Form and e-Reporting e-Form:
The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).

How to Download on Android Phones
 
  1. Scan the QR Code by pressing the link
  2. Click the three dots in the top-right corner
  3. Choose Install app
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app
 
How to Download on Apple IOS Phones
 
  1. Scan the QR Code by pressing the link
  2. Click on the share button
  3. Add VigiMobile to the home screen
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Windows
  1. Press on the link
  2. Install from the Browser menu
  3. VigiMobile e-Form/e-Reporting e-Form is now installed 
 
Scan QR Codes to Report:
  1. ADRs Following Medication Use
  1. AEFIs Following Vaccine Use
Or use the following link: LNPVP: e-Reporting eForm Or use the following link: LNPVP: VigiMobile eForm
 
  1. Direct Contact with the Lebanese National Pharmacovigilance Program:
You may contact the Lebanese National Pharmacovigilance Program through:
  • Email Address:
  • Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254   
 
  1.  For Market Authorization Holders:
Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines

(https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Karar%20181-2021.pdf).

All XML files should be sent to the following emails: pv@moph.gov.lb, and pv.moph@gmail.com.
 
As for what to report or report type, you can refer to Module VI:
https://moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon#/en/view/70479/lebanese-guideline-on-good-pharmacovigilance-practices-lgvp-
 
    1
    ...
ATC Name ↓ B/G Ingredients Dosage Form Price
S01AA26 AZYTER G Azithromycin (dihydrate) - 15mg/g 15mg/g Drops solution 412,560 L.L
J01FA10 AZOX 250 G Azithromycin (dihydrate) - 250mg 250mg Capsule 346,711 L.L
S01EC04 AZOPT B Brinzolamide - 10mg/ml 10mg/ml Drops suspension 804,962 L.L
D07XC04 AZONIT - D G Diflucortolone valerate - 1mg/g, Isoconazole nitrate - 10mg/g Cream 225,766 L.L
J01FA10 AZOMYNE G Azithromycin (dihydrate) - 250mg 250mg Capsule 385,683 L.L
J01FA10 AZOMYNE G Azithromycin (dihydrate) - 200mg/5ml 200mg/5ml Powder for suspension 237,860 L.L
J01FA10 AZOMYCIN G Azithromycin (dihydrate) - 250mg 250mg Capsule 361,494 L.L
J01FA10 AZOMYCIN G Azithromycin (dihydrate) - 200mg/5ml 200mg/5ml Powder for suspension 693,423 L.L
J01FA10 AZOMYCIN G Azithromycin (dihydrate) - 200mg/5ml 200mg/5ml Powder for suspension + solvent 365,525 L.L
J01FA10 AZM-500 G Azithromycin - 500mg 500mg Tablet, film coated 448,843 L.L
J01FA10 AZIFAST 500 G Azithromycin - 500mg 500mg Tablet, film coated 573,373 L.L
J01FA10 AZIFAST 250 G Azithromycin - 250mg 250mg Tablet, film coated 423,630 L.L
J01FA10 AZICIN 500 BENTA G Azithromycin - 500mg 500mg Tablet, film coated 573,373 L.L
J01FA10 AZICIN 250 BENTA G Azithromycin - 250mg 250mg Tablet, film coated 423,630 L.L
L01BC07 AZACITIDINE SPC G Azacitidine - 100mg 100mg Injectable powder 10,706,993 L.L
L01BC07 AZACITIDINE NEAPOLIS G Azacitidine - 100mg 100mg Injectable lyophilised powder 9,401,575 L.L
L01BC07 AZACITIDINE EVER PHARMA G Azacitidine - 100mg/100ml 25mg/ml Injectable powder for suspension 10,967,854 L.L
L01BC07 AZACITIDINE ARROW G Azacitidine - 25mg/ml 25mg/ml Injectable suspension 10,967,854 L.L
J01DD04 AXONE 500MG IM G Ceftriaxone (sodium) - 500mg 500mg Injectable powder for solution+diluent 393,746 L.L
J01DD04 AXONE 1G IM G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution+diluent 438,093 L.L
J01DD04 AXONE G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution 4,053,029 L.L
A02BC01 AXIPRON G Omeprazole - 20mg 20mg Capsule 373,358 L.L
J01DC02 AXETINE G Cefuroxime sodium - 1.5g 1.5g Injectable powder for solution 2,273,782 L.L
J01DC02 AXETINE G Cefuroxime sodium - 750mg 750mg Injectable powder for solution 1,193,332 L.L
D10AD01 AVOTIN-A G Tretinoin - 0.05% 0.05% Cream 440,780 L.L
D11AX11 AVOQUIN G Hydroquinone - 4% 4% Cream 916,501 L.L
L03AB07 AVONEX BioTech Interferon beta-1a - 30mcg/0.5ml 30mcg/0.5ml Injectable solution 70,488,764 L.L
G04CB02 AVODART B Dutasteride - 0.5mg 0.5mg Capsule 2,660,787 L.L
R01AD09 AVOCOM G Mometasone furoate - 0.05% 0.05% Spray 419,279 L.L
D04AB01 AVOCAINE G Lidocaine - 10% 10% Spray 620,855 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025